Related Experiment Video
Updated: May 7, 2026

Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance
Published on: May 2, 2018
Characterization of KPC-160, a novel Ω-loop-deleted KPC variant on a dual-copy plasmid that confers cefiderocol
Yuxuan Liu1,2, Hanxu Hong1,2, Qisen Huang1
1Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Abstract:
The evolution of KPC-type carbapenemase variants is a major driver of resistance in Klebsiella pneumoniae. Cefiderocol (FDC), a next-generation siderophore cephalosporin, demonstrates potent activity against many KPC producers; however, emerging variants are compromising its efficacy. Here, we report the identification and functional characterization of a novel KPC variant, KPC-160, which confers resistance to FDC. This variant, harboring a unique two-amino acid deletion (ΔGlu167-Leu168) within the Ω-loop, was discovered in a clinical ST15-KL19 Klebsiella pneumoniae isolate. Antimicrobial susceptibility testing, whole-genome sequencing, and conjugation assays defined the resistance profile and genetic context, while carbapenemase activity assays, enzyme kinetics, and molecular modeling elucidated the functional mechanism. Strain K1661 exhibited FDC resistance (MIC = 8 µg/mL) alongside multidrug resistance. Genomic analysis identified the novel blaKPC-160 variant carried on an IncFIB(K) plasmid in dual IS26-flanked copies, displaying efficient transfer frequencies (3.73 × 10⁻³-4.55 × 10⁻⁵). Compared with blaKPC-2, blaKPC-160 featured a ΔGlu167-Leu168 deletion, which markedly increased FDC MICs (16-fold higher than KPC-2) and increased its affinity for FDC. Molecular docking and dynamics simulations indicated that this deletion stabilized FDC binding within the active site, thereby facilitating resistance. Conventional carbapenemase detection assays (mCIM, GeneXpert Carba-R, and NG-Test Carba 5) successfully identified KPC-160. These findings describe blaKPC-160, a deletion variant conferring clinically relevant FDC resistance via enhanced interaction and compromised inhibition. Its localization on a highly transmissible plasmid with a dual-copy architecture underscores its potential for rapid dissemination. Continuous genomic surveillance of emerging KPC variants is critical to preserving the clinical utility of FDC.
Insights
A new carbapenemase variant, KPC-160, causes cefiderocol (FDC) resistance in Klebsiella pneumoniae due to a specific deletion. This finding highlights the need for ongoing genomic surveillance to combat antimicrobial resistance.
Area of Science:
- Microbiology
- Molecular Biology
- Genetics
Background:
- Carbapenemase-type carbapenemases (KPC) are a significant cause of Klebsiella pneumoniae resistance.
- Cefiderocol (FDC) is a cephalosporin effective against many KPC producers, but emerging variants threaten its utility.
Purpose of the Study:
- To identify and functionally characterize a novel KPC variant, KPC-160, responsible for cefiderocol (FDC) resistance.
- To elucidate the mechanism by which KPC-160 confers FDC resistance.
Main Methods:
- Whole-genome sequencing and antimicrobial susceptibility testing were used to identify and define the resistance profile of the KPC-160 variant.
- Carbapenemase activity assays, enzyme kinetics, and molecular modeling were employed to understand the functional mechanism of resistance.
- Conjugation assays and plasmid analysis determined the genetic context and transferability of the blaKPC-160 variant.
Main Results:
- A novel KPC variant, KPC-160, with a two-amino acid deletion (ΔGlu167-Leu168) in the Ω-loop was identified in a clinical Klebsiella pneumoniae isolate (K1661).
- KPC-160 conferred significant FDC resistance (16-fold higher MIC than KPC-2) and multidrug resistance.
- Molecular modeling indicated the deletion stabilizes FDC binding in the active site, leading to resistance.
- The blaKPC-160 variant was found on an IncFIB(K) plasmid in dual IS26-flanked copies, showing efficient transfer.
Conclusions:
- The blaKPC-160 deletion variant confers clinically relevant FDC resistance through enhanced FDC binding and compromised inhibition.
- The presence of blaKPC-160 on a highly transmissible, dual-copy plasmid poses a risk for rapid dissemination.
- Continuous genomic surveillance for emerging KPC variants is crucial for preserving FDC's clinical effectiveness.
More Related Videos
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
06:30A Non-Coding Small RNA MicC Contributes to Virulence in Outer Membrane Proteins in Salmonella Enteritidis
Published on: January 27, 2021
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Antibiotic Selection